DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Tokyo Big Sight

2018 年 11 月 11 日 9:30 上午 - 2018 年 11 月 13 日 5:40 下午

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

15th DIA Japan Annual Meeting 2018

Innovative technologies such as AI, big data/genomics, and cell/gene therapies are poised to transform healthcare product development across the globe – join us to discuss these topics.

[V6-S6] Evidence Generation under Japan’s New Clinical Trials Act

Session Chair(s)

Shinzo  Hiroi, PhD, MPH, RPh, PMP

Shinzo Hiroi, PhD, MPH, RPh, PMP

Head of Global Medical Affairs

Shionogi & Co., Ltd., Japan

It would become more complicated to conduct interventional studies due to new clinical trials act, effective in April 2018 in Japan. The importance of observational studies has been focused to generate the medical evidence originated from Japan. In this session, the advantages and limitations of observational studies will be discussed, compared with those of interventional studies.

Speaker(s)

Akihito  Uda, MPH

Case Studies of Real World Evidence in HEOR of Pharmaceutical Industry

Akihito Uda, MPH

Novartis Pharma K.K., Japan

HEOR Group, Market Access and Public Affairs Division

Koji  Iwasaki, PhD

Impact of Clinical Trial Act on Generating Medical Evidence

Koji Iwasaki, PhD

Osaka University Hospital, Japan

Professor, Academic Clinical Research Center,

Hisashi  Urushihara, DrPH

Basics of Observational Study

Hisashi Urushihara, DrPH

Keio University, Japan

Professor, Faculty of Pharmacy, Department of Pharmacy

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。